More recently, cancers with defects in the DNA mismatch repair (MMR) pathway have been shown to have enhanced response to immune checkpoint signaling (39), and MMR cancers with wild type p53 are responsive to inhibition of the DNA repair gene WRN (40,41). This evidence concerns the gene TP53 and cancer.